Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01234558 · ClinicalTrials.gov registry record · Phase 2
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
A Phase 2 study, sponsored by Naurex, Inc, an affiliate of Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT01234558 is a Phase 2 study that has completed, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 115 participants.
The verdict
NCT01234558, a Phase 2 study, has completed, sponsored by Naurex, Inc, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
Interventions
- DRUG GLYX-13
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01234558
The ClinicalTrials.gov registry entry for NCT01234558 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Naurex, Inc, an affiliate of Allergan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GLYX-13 is the first listed.
NCT01234558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01234558 about?
NCT01234558 is a clinical study titled "Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression". The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
What is the current status of trial NCT01234558?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2011-05. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01234558?
The interventions under investigation include: GLYX-13 (DRUG).
Who is sponsoring clinical trial NCT01234558?
This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.